Key takeaways:
Trastuzumab (Herceptin) is a biologic medication. It treats certain types of breast cancer and stomach cancer.
There are currently five trastuzumab biosimilars available in the U.S. They include Ogivri (trastuzumab-dkst), Herzuma (trastuzumab-pkrb), and Ontruzant (trastuzumab-dttb). Trazimera (trastuzumab-bvzr) and Kanjinti (trastuzumab-anns) are also available.
Biosimilars are a type of biologic medication that are “highly similar” to another biologic. Biosimilars are considered just as safe and effective as the original biologic, but they’re usually more affordable.
Herceptin (trastuzumab) is a widely-used biologic medication. It treats certain types of HER2-positive cancer, including breast cancer and gastric (stomach) cancer. Over the years, it has become a standard treatment for many people living with HER2-positive cancer. So in an effort to make this highly-touted treatment more accessible, five trastuzumab biosimilars have been approved in the U.S. since 2017.
If you or a loved one have been diagnosed with a HER2-positive cancer, Herceptin or a trastuzumab biosimilar may be a treatment option for you. But what is a biosimilar? And how do they stack up to Herceptin?
Herceptin, also known as trastuzumab, is an injectable biologic medication. Biologics are complex medications that are produced from living or natural resources, such as bacteria, proteins, or sugars. Herceptin is typically given as an intravenous (IV) infusion every 1 to 3 weeks, and you can receive it by itself or in combination with chemotherapy.
An interchangeable biosimilar to Humira® for 92% less
Introducing Adalimumab-adbm, an autoimmune medication that is the first-ever FDA-approved interchangeable biosimilar to Humira®. Get it for 92% less than the Humira® list price.
After it’s infused, Herceptin fights cancer in a specific way. It’s a targeted therapy medication known as a human epidermal growth factor receptor 2 (HER2) blocker. HER2 is a protein that helps cancer cells grow rapidly. By targeting and blocking HER2, Herceptin tells cancer cells to stop growing. Cancers that have a higher amount of HER2 receptors (chemical binding sites) are called “HER2-positive.”
Due to how it works, Herceptin is approved to treat certain types of HER2-positive breast cancer and HER2-positive stomach cancer. It may also be used off-label for other types of cancer, like HER2-positive endometrial cancer or colorectal cancer.
Herceptin was initially approved in 1998 for metastatic HER2-positive breast cancer. Since then, it has helped enhance the treatments of many people living with HER2-positive cancer. However, the need for more affordable treatment options for HER2-positive cancer has only grown.
That's where trastuzumab biosimilars come in. Biosimilars are a type of biologic medication that are highly similar to their original (reference) biologic. You can expect them to work the same way as their original biologic, and have similar side effects. But they often come with a lower price tag.
In various studies, the five trastuzumab biosimilars have proven to be comparable to their original biologic: Herceptin. All trastuzumab biosimilars are approved to treat the same cancers as Herceptin, and they also have the same dosages.
Note: Herceptin Hylecta (trastuzumab/hyaluronidase) is another form of trastuzumab that’s administered subcutaneously (under the skin). Trastuzumab biosimilars are only biosimilar to Herceptin, not Herceptin Hylecta.
Let’s look at each biosimilar a little more closely.
In December 2017, Ogivri (trastuzumab-dkst) became the first trastuzumab biosimilar to be approved. Like Herceptin, it’s approved to treat HER2-positive breast and stomach cancer. Clinical studies show that Ogivri's safety and effectiveness is comparable to Herceptin.
For instance, Ogivri was compared to Herceptin in combination with chemotherapy in a study of people with HER2-positive breast cancer. People who received Ogivri had a response rate of about 70%, meaning 70% of people saw their cancer shrink or disappear. Those who received Herceptin had a similar response rate. Other studies, like lab studies, also confirm there’s no clinically meaningful differences between the two.
However, some differences between Ogivri and Herceptin do exist. Ogivri is formulated with inactive ingredients that differ from Herceptin. It contains PEG 3350 and sorbitol, while Herceptin and the other approved trastuzumab biosimilars do not. If you’re scheduled to receive multiple medications at the clinic, these inactive ingredients could slightly impact the timing of your infusions on your appointment day.
Herzuma (trastuzumab-pkrb) was the second approved trastuzumab biosimilar. It was approved in December 2018.
Like Ogivri, Herzuma was compared to Herceptin in combination with chemotherapy in a clinical trial of people with HER2-positive breast cancer. In this study, people who received Herzuma had a pathologic complete response rate of about 47%. People receiving Herceptin had similar results. Herzuma and Herceptin were found to be comparably safe and effective.
Note: A pathologic complete response means that there were no remaining signs of cancer found in surgically-removed tissue.
Ontruzant (trastuzumab-dttb) is the third Herceptin biosimilar. It was approved shortly after Herzuma in January 2019.
One key study compared Ontruzant to Herceptin in people with early-stage HER2-positive breast cancer. People receiving Ontruzant in combination with chemotherapy had a pathologic complete response of about 52%. This was similar to people who received Herceptin.
Trazimera (trastuzumab-qyyp) became the fourth approved Herceptin biosimilar in March 2019.
Trazimera is backed by similar data. One study compared it to Herceptin in combination with chemotherapy in people with metastatic HER2-positive breast cancer. People who received Trazimera had a response rate of about 63%, which was similar to Herceptin.
The fifth and most recent Herceptin biosimilar to gain approval in the U.S. was Kanjinti (trastuzumab-anns). The FDA approved it in June 2019.
Kanjinti was compared to Herceptin in a clinical trial of people with early HER2-positive breast cancer. People who received Kanjinti had a pathologic complete response rate of 48%. Like the other studies, people who received Herceptin had a similar response.
Kanjinti is also the only trastuzumab biosimilar that has transition study data available. This means that Kanjinti was studied in people who were receiving Herceptin and then switched their treatment to Kanjinti. This study found that it was safe to switch back and forth between the two medications.
Your healthcare provider may decide to give you Kanjinti, Herceptin, or another trastuzumab biosimilar. But, it’s important to note that none of the trastuzumab biosimilars have technically been deemed interchangeable biosimilars.
Trastuzumab biosimilars haven’t been directly compared to each other, so we don’t know if one is better than another. But based on how they’re made, it isn’t expected for there to be any clinically meaningful differences between them.
What’s available at your cancer center — and your expected out-of-pocket costs — will help determine which trastuzumab biosimilar you’ll receive. Your cancer center may stock all, some, or one of the trastuzumab biosimilars on their formulary. Your health insurance may also prefer to cover Herceptin itself, one biosimilar product specifically, or some combination of the two. Most insurance plans cover at least one Herceptin biosimilar.
If you’re uninsured or underinsured, there may be other ways to save. Manufacturer savings programs are one example. Some of these programs for Herceptin and its biosimilars are the Teva Shared Solutions for Biosimilars, Amgen’s Assist360, and Pfizer Oncology Co-pay Savings Program. The savings program you qualify for may help determine which product you’ll get.
Five biosimilars to Herceptin are currently available. They include Ogivri, Herzuma, and Ontruzant. Trazimera and Kanjinti are also available.
Trastuzumab biosimilars are highly comparable in safety and effectiveness to Herceptin, and they may be more affordable. Speak with your oncologist to see if Herceptin or one of its biosimilars are an option for you.
American Cancer Society. (2021). What is stomach cancer?
American Cancer Society. (2022). Breast cancer HER2 status.
Amgen, Inc. (2022). Kanjinti [package insert].
Aykan, N. F., et al. (2020). Objective response rate assessment in oncology: Current situation and future expectations.World Journal of Clinical Oncology.
Nichols, S. (2022). What are anti-HER2 therapies? Breastcancer.org.
Cephalon, Inc. (2022). Herzuma [package insert].
Genentech, Inc. (2020). Herceptin hylecta [package insert].
Genentech, Inc. (2021). Herceptin [package insert].
Merck Sharp & Dohme Corp. (2020). Ontruzant [package insert].
Mylan Institutional, LLC. (2021). Ogivri [package insert].
National Cancer Institute Dictionary of Cancer Terms. (n.d.). Pathologic complete response. National Cancer Institute.
Pegram, M.D., et al. (2019). PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.British Journal of Cancer.
Pfizer Inc. (2022). Trazimera [package insert].
Pivot, X., et al. (2018). Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2–positive early breast cancer.Journal of Clinical Oncology.
Rugo, H.S., et al. (2017). Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–positive metastatic breast cancer.Journal of the American Medical Association.
Stebbing, J., et al. (2017). CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: A randomised, double-blind, active-controlled, phase 3 equivalence trial.The Lancet Oncology.
U.S. Food and Drug Administration. (n.d.). Biological product definitions.
U.S. Food and Drug Administration. (1998). Trastuzumab, Genentech Herceptin approval letter.
U.S. Food and Drug Administration. (2022). Inactive ingredients in approved drug products search: Frequently asked questions.
Von Minckwitz, G., et al. (2018). Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.The Lancet Oncology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.